AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28472530 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 148
Study 28472530 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention for 3 months
Number of subjects: 148
Study 26517656 — intervention group
Group type: EXPERIMENTAL
Intervention: 17D-213/77
Number of subjects: 1966
Study 26517656 — intervention group
Group type: EXPERIMENTAL
Intervention: 17DD
Number of subjects: 1966
Study 26517656 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant vaccination against measles, mumps and rubella
Number of subjects: 1966
Study 23147558 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP+SDD (20 mg of doxycycline twice daily)
Number of subjects: 174
Study 23147558 — intervention group
Group type: COMPARATOR
Intervention: SRP+placebo
Number of subjects: 174
Study 21059422 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate treatment
Number of subjects: 52
Study 21059422 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 20024763 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use at last sex in non-spousal partnerships
Number of subjects: 762
Study 20024763 — intervention group
Group type: EXPERIMENTAL
Intervention: New HIV infection
Number of subjects: 762
Study 17519642 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5 mg for 1 month, 5 mg for 2 months)
Number of subjects: 30
Study 17519642 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy + Olanzapine
Number of subjects: 30
Study 17519642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15375277 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 0
Study 15375277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15471832 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐FLT PET
Number of subjects: 17
Study 15471832 — intervention group
Group type: COMPARATOR
Intervention: 18F‐FDG PET
Number of subjects: 17
Study 11423814 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pyridoxine (5 g over 5 minutes)
Number of subjects: 5
Study 11423814 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo (50 mL of normal saline solution)
Number of subjects: 5
Study 9208341 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine with cerivastatin
Number of subjects: 0
Study 9208341 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine pretreatment 1 hour before cerivastatin
Number of subjects: 0
Study 9208341 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine pretreatment 5 hours before cerivastatin
Number of subjects: 0
Study 8094168 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg aspirin daily until delivery
Number of subjects: 1106
Study 8094168 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 1106
Study 3620286 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline with amoxycillin
Number of subjects: 0
Study 3620286 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline with erythromycin
Number of subjects: 0
Study 3620286 — intervention group
Group type: COMPARATOR
Intervention: Theophylline with erythromycin
Number of subjects: 0
Study 31940793 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional neural network for PPI site prediction; improved data set; specific details on dosage and duration not applicable.
Number of subjects: 0
Study 31940793 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional neural network for PPI site prediction; high binding propensity samples.
Number of subjects: 0
Study 28664457 — intervention group
Group type: COMPARATOR
Intervention: Highest tertile of MCV
Number of subjects: 403
Study 28664457 — intervention group
Group type: COMPARATOR
Intervention: Highest tertile of MCH
Number of subjects: 403
Study 28664457 — intervention group
Group type: COMPARATOR
Intervention: Highest tertile of MCHC
Number of subjects: 403
Study 28664457 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined second and third tertiles of MCV
Number of subjects: 403
Study 28664457 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined second and third tertiles of MCH
Number of subjects: 403
Study 28664457 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined second and third tertiles of MCHC
Number of subjects: 403
Study 26938140 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg)
Number of subjects: 300
Study 26938140 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1 g)
Number of subjects: 300
Study 26938140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 26938140 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg) and Acetaminophen (1 g)
Number of subjects: 300
Study 25605843 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFIRI (fluorouracil, leucovorin, and irinotecan)
Number of subjects: 666
Study 25605843 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI alone
Number of subjects: 666
Study 23263176 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy (ART) initiated at enrollment (n = 139)
Number of subjects: 284
Study 23263176 — intervention group
Group type: COMPARATOR
Intervention: Deferred antiretroviral therapy (ART) initiated when CD4 count <15% or CDC category C event developed (n = 145)
Number of subjects: 284
Study 23263176 — intervention group
Group type: COMPARATOR
Intervention: HIV-uninfected children (n = 319)
Number of subjects: 284
Study 21395483 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone 20 mg
Number of subjects: 15
Study 21395483 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/Naloxone 20/10 mg
Number of subjects: 15
Study 21395483 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone 10 mg
Number of subjects: 15
Study 18339123 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg/day)
Number of subjects: 115
Study 18339123 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (600 mg/day)
Number of subjects: 115
Study 18339123 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg/day) and Vitamin E (600 mg/day)
Number of subjects: 115
Study 18339123 — intervention group
Group type: COMPARATOR
Intervention: No melatonin treatment
Number of subjects: 115
Study 16797388 — intervention group
Group type: EXPERIMENTAL
Intervention: GLA 2.2% cream
Number of subjects: 17
Study 16797388 — intervention group
Group type: COMPARATOR
Intervention: Placebo-based cream
Number of subjects: 17
Study 12506030 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood stem cell recipients
Number of subjects: 87
Study 12506030 — intervention group
Group type: COMPARATOR
Intervention: Marrow recipients
Number of subjects: 87
Study 12506030 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretransplantation antibody levels in the recipient
Number of subjects: 87
Study 12506030 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor pretransplantation antibody levels
Number of subjects: 87
Study 12506030 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient or donor age, total body irradiation, and graft‐versus‐host disease or its treatment
Number of subjects: 87
Study 10730983 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oxytocin infusion (1:9 mg/d) on Days 14 to 26 after estrus
Number of subjects: 25
Study 10730983 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin injections (0.33 USP units/kg body weight, s.c.) twice daily on Days 3 to 6 of the estrous cycle
Number of subjects: 25
Study 10730983 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oxytocin infusion
Number of subjects: 25
Study 10730983 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 25
Study 10160459 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line medical command (OLMC) randomization
Number of subjects: 87
Study 1466940 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (0.5 mg) syrup, 2.5 mL twice daily
Number of subjects: 113
Study 1466940 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup, 2.5 mL twice daily
Number of subjects: 113
Study 6429229 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 36
Study 6429229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31907033 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT) using the PICO™ system
Number of subjects: 38
Study 31907033 — intervention group
Group type: COMPARATOR
Intervention: Standard postsurgical wound care
Number of subjects: 38
Study 30446822 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 125
Study 30446822 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational group (OCD-EP)
Number of subjects: 125
Study 27308725 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Stroop Task (EST) with blocked presentation
Number of subjects: 67
Study 27308725 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Stroop Task (EST) with randomized presentation
Number of subjects: 67
Study 27308725 — intervention group
Group type: COMPARATOR
Intervention: Non-traumatized controls
Number of subjects: 67
Study 25941925 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-casein hydrolysate
Number of subjects: 8
Study 25941925 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-whey hydrolysate
Number of subjects: 8
Study 25941925 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-only
Number of subjects: 8
Study 25941925 — intervention group
Group type: COMPARATOR
Intervention: Placebo-water
Number of subjects: 8
Study 24405719 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Number of subjects: 0
Study 22529693 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic duct stent placement
Number of subjects: 120
Study 22529693 — intervention group
Group type: COMPARATOR
Intervention: Non-stent group
Number of subjects: 120
Study 20000282 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-assisted activity (weekly for 2 months)
Number of subjects: 30
Study 20000282 — intervention group
Group type: COMPARATOR
Intervention: Control group (no animal-assisted activity)
Number of subjects: 30
Study 17322140 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PJ) 8 oz
Number of subjects: 13
Study 17322140 — intervention group
Group type: COMPARATOR
Intervention: Grapefruit juice (GFJ) 8 oz
Number of subjects: 13
Study 15356495 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended prophylaxis regimen including regular mechanical tooth cleaning by a hygienist, scaling, and chlorhexidine treatment.
Number of subjects: 80
Study 15356495 — intervention group
Group type: COMPARATOR
Intervention: Initial prophylaxis alone consisting of patient motivation, oral hygiene checkups, and fluoridation.
Number of subjects: 80
Study 15356495 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient selection based on caries risk indicators.
Number of subjects: 80
Study 12073159 — intervention group
Group type: EXPERIMENTAL
Intervention: THC-only (low dose)
Number of subjects: 25
Study 12073159 — intervention group
Group type: EXPERIMENTAL
Intervention: THC-only (high dose)
Number of subjects: 25
Study 12073159 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-plant marijuana (low dose)
Number of subjects: 25
Study 12073159 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-plant marijuana (high dose)
Number of subjects: 25
Study 12073159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 10445600 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1,000 microg/day
Number of subjects: 33
Study 10445600 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 2,000 microg/day
Number of subjects: 33
Study 10445600 — intervention group
Group type: COMPARATOR
Intervention: Control group A: Low dose inhaled corticosteroids (< or =400 microg/day)
Number of subjects: 33
Study 10445600 — intervention group
Group type: COMPARATOR
Intervention: Control group B: Oral corticosteroids (> or =10 mg/day)
Number of subjects: 33
Study 10445600 — intervention group
Group type: COMPARATOR
Intervention: Control group C: Healthy untreated volunteers
Number of subjects: 33
Study 10445600 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 33
Study 10445600 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 33
Study 7769071 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic injection with live spermatozoa
Number of subjects: 0
Study 7769071 — intervention group
Group type: COMPARATOR
Intervention: Intracytoplasmic injection with dead spermatozoa
Number of subjects: 0
Study 7769071 — intervention group
Group type: COMPARATOR
Intervention: Intracytoplasmic injection without a spermatozoon
Number of subjects: 0
Study 7769071 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic injection of human sperm cytosolic fraction (CF)
Number of subjects: 0
Study 7769071 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic injection of human sperm cytosolic fraction (CF) in mouse oocytes
Number of subjects: 0
Study 7769071 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic injection of CF after heat treatment
Number of subjects: 0
Study 2179521 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol treatment for 26 days
Number of subjects: 19
Study 435348 — intervention group
Group type: EXPERIMENTAL
Intervention: Metallized plastic sheeting (m.p.s.)
Number of subjects: 42
Study 435348 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study 6849726 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrimeprazine 7.5 mg i.m.
Number of subjects: 10
Study 6849726 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 5 mg
Number of subjects: 10
Study 6849726 — intervention group
Group type: COMPARATOR
Intervention: Methotrimeprazine (small non-sedative doses)
Number of subjects: 10
Study 30579966 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine + Busulfan (FB)
Number of subjects: 60
Study 30579966 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine + Thiotepa (FT)
Number of subjects: 60
Study 30407932 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS treatment
Number of subjects: 665
Study 30407932 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of rTMS treatment based on cBEI
Number of subjects: 665
Study 26403637 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 195
Study 26403637 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 195
Study 26403637 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EES and SES)
Number of subjects: 195
Study 25046950 — intervention group
Group type: EXPERIMENTAL
Intervention: Shen‐reinforcing and menstrual cycle‐regulating therapy combined with Western medicine (IM group)
Number of subjects: 78
Study 25046950 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (WM group)
Number of subjects: 78
Study 22296973 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol valerate (2 · 2 mg daily for 6–10 days)
Number of subjects: 86
Study 22296973 — intervention group
Group type: COMPARATOR
Intervention: Standard ovarian stimulation protocol (Control)
Number of subjects: 86
Study 20435238 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH + MgSO(4)
Number of subjects: 38
Study 20435238 — intervention group
Group type: COMPARATOR
Intervention: ACTH (control)
Number of subjects: 38
Study 18544168 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple educational intervention for GPs
Number of subjects: 376
Study 18544168 — intervention group
Group type: COMPARATOR
Intervention: Complex educational intervention for GPs (including clinical outreach visit)
Number of subjects: 376
Study 14715345 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose reteplase
Number of subjects: 0
Study 14715345 — intervention group
Group type: COMPARATOR
Intervention: Half-dose reteplase with full-dose abciximab
Number of subjects: 0
Study 11689803 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult ischemic preconditioning
Number of subjects: 80
Study 11689803 — intervention group
Group type: COMPARATOR
Intervention: Adult control
Number of subjects: 80
Study 11689803 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged ischemic preconditioning
Number of subjects: 80
Study 11689803 — intervention group
Group type: COMPARATOR
Intervention: Aged control
Number of subjects: 80
Study 9297428 — intervention group
Group type: EXPERIMENTAL
Intervention: rH‐EPO (200 U/kg body weight subcutaneously once a day, three days a week for 4 weeks) with oral ferrous sulfate (4 mg/kg/day)
Number of subjects: 58
Study 9297428 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 58
Study 9297428 — intervention group
Group type: EXPERIMENTAL
Intervention: rH‐EPO
Number of subjects: 58
Study 7952423 — intervention group
Group type: EXPERIMENTAL
Intervention: Early percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 108
Study 7952423 — intervention group
Group type: COMPARATOR
Intervention: Early medical therapy
Number of subjects: 108
Study 7952423 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 108
Study 7952423 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 108
Study 3674795 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral physostigmine (mode = 13 mg/day)
Number of subjects: 22
Study 3674795 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral physostigmine
Number of subjects: 22
Study 3674795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31942840 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (100 mg) in addition to standard treatment
Number of subjects: 49
Study 31942840 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment only
Number of subjects: 49
Study 31942840 — intervention group
Group type: COMPARATOR
Intervention: Healthy non-diabetic pediatric subjects (control group)
Number of subjects: 49
Study 29927937 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge eating symptoms (BE)
Number of subjects: 817
Study 29927937 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual trauma
Number of subjects: 817
Study 29927937 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 817
Study 29927937 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 817
Study 27788877 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based asthma intervention
Number of subjects: 150
Study 25188544 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Process-oriented training for health professionals
Number of subjects: 540
Study 25188544 — intervention group
Group type: COMPARATOR
Intervention: Control Group A (CGA) - No intervention
Number of subjects: 540
Study 25188544 — intervention group
Group type: COMPARATOR
Intervention: Control Group B (CGB) - No intervention
Number of subjects: 540
Study 22348399 — intervention group
Group type: EXPERIMENTAL
Intervention: GP endorsed reminder and duplicate FOBt kit
Number of subjects: 4380
Study 22348399 — intervention group
Group type: COMPARATOR
Intervention: No additional contact
Number of subjects: 4380
Study 20346716 — intervention group
Group type: EXPERIMENTAL
Intervention: PedMIDAS
Number of subjects: 1585
Study 17424883 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable dressing
Number of subjects: 35
Study 17424883 — intervention group
Group type: COMPARATOR
Intervention: Standard nonabsorbable sinus packs
Number of subjects: 35
Study 16359284 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced QRS duration <190 ms (Group A, n=77)
Number of subjects: 92
Study 16359284 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced QRS duration >=190 ms (Group B, n=15)
Number of subjects: 92
Study 16359284 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced QRS duration
Number of subjects: 92
Study 16359284 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced QRS duration among group A patients with CHF during follow-up
Number of subjects: 92
Study 12577242 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (200 mg/m2/d before radiation)
Number of subjects: 0
Study 12577242 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (radiation therapy 64.8 Gy, paclitaxel, carboplatin, followed by cisplatin and gemcitabine)
Number of subjects: 0
Study 15335530 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% aqueous alcohol solution
Number of subjects: 38
Study 15335530 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.10% aqueous alcohol solution
Number of subjects: 38
Study 15335530 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% aqueous alcohol solution
Number of subjects: 38
Study 15335530 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% aqueous alcohol solution (1 ml)
Number of subjects: 38
Study 15335530 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.10% aqueous alcohol solution (1 ml)
Number of subjects: 38
Study 15335530 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% aqueous alcohol solution (1 ml)
Number of subjects: 38
Study 15335530 — intervention group
Group type: COMPARATOR
Intervention: Control (distilled water)
Number of subjects: 38
Study 7975842 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine expressed in mutant yeast (non-hyperglycosylated preS2 + 2 polypeptide)
Number of subjects: 0
Study 7975842 — intervention group
Group type: COMPARATOR
Intervention: Licensed HB vaccine
Number of subjects: 0
Study 7975842 — intervention group
Group type: COMPARATOR
Intervention: Hyperglycosylated preS2 + 2 vaccine
Number of subjects: 0
Study 2633660 — intervention group
Group type: EXPERIMENTAL
Intervention: Vialon catheter
Number of subjects: 170
Study 2633660 — intervention group
Group type: COMPARATOR
Intervention: Teflon catheter
Number of subjects: 170
Study 30502508 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide oral suspension (BOS)
Number of subjects: 0
Study 30502508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28761069 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-positive patients receiving FDA-approved oncology drugs with required pharmacogenomic biomarker testing
Number of subjects: 80